# Equillium, Inc.: financial statements, quarterly

EQ · Nasdaq · CIK 1746466 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/eq.md) · [Financials](/companies/eq/financials.md) · [Filings](/companies/eq/filings.md) · [Insiders](/companies/eq/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/eq/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [8.9](/filings/0000950170-24-126322.md) | [9.2 d](/filings/0000950170-25-045726.md) | [10.7](/filings/0000950170-25-071389.md) | [13.9](/filings/0000950170-25-108834.md) | [12.2](/filings/0001193125-25-280202.md) | [4.4 d](/filings/0001193125-26-124143.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $m | [(3.6)](/filings/0000950170-24-126322.md) | [(3.2) d](/filings/0000950170-25-045726.md) | [(2.8)](/filings/0000950170-25-071389.md) | [(0.1)](/filings/0000950170-25-108834.md) | [(0.7)](/filings/0001193125-25-280202.md) | [(4.7) d](/filings/0001193125-26-124143.md) | [(8.9)](/filings/0001193125-26-221625.md) | [(6.2)](/filings/0001193125-26-349235.md) | [(4.6)](/filings/0001193125-25-280202.md) | [(4.0) d](/filings/0001193125-26-124143.md) | [(5.6)](/filings/0001193125-26-221625.md) | [(5.2)](/filings/0001193125-26-349235.md) |
| Income tax | $m | [0.5](/filings/0000950170-24-126322.md) | [0.0 d](/filings/0000950170-25-045726.md) | [0.0](/filings/0000950170-25-071389.md) | [0.0](/filings/0000950170-25-108834.md) | [0.0](/filings/0001193125-25-280202.md) | [0.4 d](/filings/0001193125-26-124143.md) | [0.0](/filings/0000950170-25-071389.md) | [0.0](/filings/0000950170-25-108834.md) | [0.0](/filings/0001193125-25-280202.md) | [0.0 d](/filings/0001193125-26-124143.md) | not reported | not reported |
| Net income | $m | [(3.7)](/filings/0000950170-24-126322.md) | [(2.3) d](/filings/0000950170-25-045726.md) | [(2.7)](/filings/0001193125-25-280202.md) | [0.5](/filings/0001193125-25-280202.md) | [(0.0)](/filings/0001193125-25-280202.md) | [(5.8) d](/filings/0001193125-26-124143.md) | [(8.7)](/filings/0001193125-26-349235.md) | [(5.7)](/filings/0001193125-26-349235.md) | [(4.2)](/filings/0001193125-25-280202.md) | [(3.8) d](/filings/0001193125-26-124143.md) | [(5.3)](/filings/0001193125-26-349235.md) | [(4.7)](/filings/0001193125-26-349235.md) |
| Diluted EPS | $ per share | [(0.11)](/filings/0000950170-24-126322.md) | not reported | [(0.08)](/filings/0000950170-25-071389.md) | [0.01](/filings/0000950170-25-108834.md) | [0.00](/filings/0001193125-25-280202.md) | not reported | [(0.24)](/filings/0001193125-26-221625.md) | [(0.16)](/filings/0001193125-26-349235.md) | [(0.06)](/filings/0001193125-25-280202.md) | not reported | [(0.06)](/filings/0001193125-26-221625.md) | [(0.04)](/filings/0001193125-26-349235.md) |
| Basic EPS | $ per share | [(0.11)](/filings/0000950170-24-126322.md) | not reported | [(0.08)](/filings/0000950170-25-071389.md) | [0.01](/filings/0000950170-25-108834.md) | [0.00](/filings/0001193125-25-280202.md) | not reported | [(0.24)](/filings/0001193125-26-221625.md) | [(0.16)](/filings/0001193125-26-349235.md) | [(0.06)](/filings/0001193125-25-280202.md) | not reported | [(0.06)](/filings/0001193125-26-221625.md) | [(0.04)](/filings/0001193125-26-349235.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: not reported
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [34.4](/filings/0000950170-23-061108.md) | [23.2](/filings/0000950170-25-045726.md) | [11.6](/filings/0000950170-24-056960.md) | [11.1](/filings/0000950170-24-093949.md) | [15.4](/filings/0000950170-24-126322.md) | [18.1](/filings/0001193125-26-124143.md) | [14.5](/filings/0000950170-25-071389.md) | [11.5](/filings/0000950170-25-108834.md) | [33.1](/filings/0001193125-25-280202.md) | [30.3](/filings/0001193125-26-349235.md) | [61.3](/filings/0001193125-26-221625.md) | [57.2](/filings/0001193125-26-349235.md) |
| Current assets | $m | [53.9](/filings/0000950170-23-061108.md) | [49.3](/filings/0000950170-25-045726.md) | [42.5](/filings/0000950170-24-056960.md) | [41.9](/filings/0000950170-24-093949.md) | [33.6](/filings/0000950170-24-126322.md) | [25.0](/filings/0001193125-26-124143.md) | [16.2](/filings/0000950170-25-071389.md) | [12.0](/filings/0000950170-25-108834.md) | [33.6](/filings/0001193125-25-280202.md) | [31.0](/filings/0001193125-26-349235.md) | [62.3](/filings/0001193125-26-221625.md) | [58.0](/filings/0001193125-26-349235.md) |
| Total assets | $m | [55.2](/filings/0000950170-23-061108.md) | [50.5](/filings/0000950170-25-045726.md) | [43.6](/filings/0000950170-24-056960.md) | [42.9](/filings/0000950170-24-093949.md) | [34.5](/filings/0000950170-24-126322.md) | [25.6](/filings/0001193125-26-124143.md) | [16.7](/filings/0000950170-25-071389.md) | [12.4](/filings/0000950170-25-108834.md) | [34.5](/filings/0001193125-25-280202.md) | [31.9](/filings/0001193125-26-349235.md) | [63.1](/filings/0001193125-26-221625.md) | [58.7](/filings/0001193125-26-349235.md) |
| Current liabilities | $m | [28.2](/filings/0000950170-23-061108.md) | [27.6](/filings/0000950170-25-045726.md) | [22.2](/filings/0000950170-24-056960.md) | [20.2](/filings/0000950170-24-093949.md) | [11.1](/filings/0000950170-24-126322.md) | [6.4](/filings/0001193125-26-124143.md) | [6.0](/filings/0000950170-25-071389.md) | [7.2](/filings/0000950170-25-108834.md) | [3.1](/filings/0001193125-25-280202.md) | [2.9](/filings/0001193125-26-349235.md) | [3.3](/filings/0001193125-26-221625.md) | [2.5](/filings/0001193125-26-349235.md) |
| Total liabilities | $m | [31.1](/filings/0000950170-23-061108.md) | [28.0](/filings/0000950170-25-045726.md) | [22.5](/filings/0000950170-24-056960.md) | [20.4](/filings/0000950170-24-093949.md) | [11.3](/filings/0000950170-24-126322.md) | [6.5](/filings/0001193125-26-124143.md) | [6.2](/filings/0000950170-25-071389.md) | [7.3](/filings/0000950170-25-108834.md) | [3.6](/filings/0001193125-25-280202.md) | [3.3](/filings/0001193125-26-349235.md) | [3.6](/filings/0001193125-26-221625.md) | [2.7](/filings/0001193125-26-349235.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [24.1](/filings/0000950170-24-126322.md) | [22.6](/filings/0001193125-26-124143.md) | [21.1](/filings/0001193125-25-280202.md) | [22.4](/filings/0001193125-25-280202.md) | [23.2](/filings/0001193125-25-280202.md) | [19.1](/filings/0001193125-26-349235.md) | [10.6](/filings/0001193125-26-349235.md) | [5.1](/filings/0001193125-26-349235.md) | [30.9](/filings/0001193125-25-280202.md) | [28.6](/filings/0001193125-26-349235.md) | [59.5](/filings/0001193125-26-349235.md) | [56.0](/filings/0001193125-26-349235.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(1,909) d](/filings/0000950170-24-126322.md) | [(5,664) d](/filings/0000950170-25-045726.md) | [(8,800)](/filings/0000950170-25-071389.md) | [730 d](/filings/0000950170-25-108834.md) | [(7,657) d](/filings/0001193125-25-280202.md) | [(3,299) d](/filings/0001193125-26-124143.md) | [(8,169)](/filings/0001193125-26-221625.md) | [(3,013) d](/filings/0001193125-26-349235.md) | [(8,431) d](/filings/0001193125-25-280202.md) | [(3,133) d](/filings/0001193125-26-124143.md) | [(4,301)](/filings/0001193125-26-221625.md) | [(4,107) d](/filings/0001193125-26-349235.md) |
| Capital expenditure | $k | not reported | [35.0 d](/filings/0000950170-25-045726.md) | [19.0](/filings/0000950170-25-071389.md) | [62.0 d](/filings/0000950170-25-108834.md) | [0.0 d](/filings/0001193125-25-280202.md) | [4.0 d](/filings/0001193125-26-124143.md) | [4.0](/filings/0001193125-26-221625.md) | [0.0 d](/filings/0001193125-26-349235.md) | [0.0 d](/filings/0001193125-25-280202.md) | [44.0 d](/filings/0001193125-26-124143.md) | [3.0](/filings/0001193125-26-221625.md) | [71.0 d](/filings/0001193125-26-349235.md) |
| Share repurchases | $k | not reported | [0.0 d](/filings/0000950170-25-045726.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [34.4](/filings/0000950170-23-061108.md) | [34.4](/filings/0000950170-24-056960.md) | [34.4](/filings/0000950170-24-093949.md) | [34.9](/filings/0000950170-24-126322.md) | [35.3](/filings/0000950170-25-071389.md) | [36.6](/filings/0000950170-25-108834.md) | [35.4](/filings/0001193125-25-280202.md) | [35.6](/filings/0001193125-26-221625.md) | [35.7](/filings/0001193125-26-349235.md) | [65.3](/filings/0001193125-25-280202.md) | [96.3](/filings/0001193125-26-221625.md) | [112](/filings/0001193125-26-349235.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 63,408,082 at 2026-08-07, from the cover of the [10-Q filed 2026-08-13](/filings/0001193125-26-349235.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.